Skip to content
Xylose
Xylo-pfan (xylose) is a small molecule pharmaceutical. Xylose was first approved as Xylo-pfan on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Xylose
Tradename
Company
Number
Date
Products
XYLOSELyne LaboratoriesN-018856 DISCN1987-03-26
1 products
XYLO-PFANSavage LaboratoriesN-017605 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E8411147
AnesthesiaD00075822116
ObesityD009765EFO_0001073E66.9112
Postoperative nausea and vomitingD020250EFO_000488811
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1124
Coronary artery diseaseD003324I25.1213
Coronary artery bypassD001026EFO_000377622
Pulmonary surgical proceduresD01351022
Post-cardiac arrest syndromeD00008094211
Coronary diseaseD00332711
Panic disorderD016584EFO_0004262F41.0111
Post-traumatic stress disordersD013313EFO_0001358F43.1111
Pulmonary embolismD011655EFO_0003827I2611
Postoperative cognitive complicationsD00007969011
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.94216
Idiopathic pulmonary fibrosisD054990J84.112123
Non-small-cell lung carcinomaD0022891113
Brain hypoxia-ischemiaD020925EFO_1000846P91.61213
Respiration disordersD012120J00-J99222
Covid-19D000086382U07.1112
VapingD0000721371112
Bronchiolitis obliteransD001989EFO_00071831112
Colorectal neoplasmsD01517911
DeliriumD003693R41.011
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung diseasesD008171EFO_0003818J98.4112
Bipolar disorderD001714EFO_0000289F30.911
Major depressive disorderD003865EFO_0003761F2211
Alzheimer diseaseD000544EFO_0000249F0311
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Premature birthD047928EFO_0003917O6011
Bronchopulmonary dysplasiaD001997P27.811
EmphysemaD004646EFO_0000464J4311
CholelithiasisD002769EFO_0004799K8011
CholecystitisD002764HP_0001082K8111
Brain diseasesD001927HP_0001298G93.4011
Marijuana smokingD00838511
Marijuana useD00007460911
Lung injuryD055370S27.3011
InfectionsD007239EFO_000054411
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameXYLOSE
INN
Description
D-xylopyranose is d-Xylose in its pyranose form.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
OC1OC[C@@H](O)[C@H](O)[C@H]1O
Identifiers
PDB
CAS-ID58-86-6
RxCUI
ChEMBL IDCHEMBL502135
ChEBI ID53455
PubChem CID135191
DrugBank
UNII ID
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 40,695 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details